Company Introduction | Hanmi Pharmaceutical

Overview

R&D-centric Biopharmaceutical Company

Hanmi Pharmaceutical is a representative Korean R&D-centric biopharmaceutical company established in 1973 by pharmacist Sung-ki Lim. We plow ahead in pursuing innovation based on our founder’s conviction as represented by his words, “Let’s use our technology to make better medicines” and his management philosophy of “Respect for humanity” and Value Creation.”

1st Highest Number of Open Innovation
Achievements
Highest Number of Independently
Developed Innovative Products
among
Korean Biopharmaceutical
Companies.
26+ Highest Number of Breakthrough
New Drug Pipelines in Korea

4.5Trillion Won Cumulative R&D Investment
AAAin CP Rating First and Only among
participating
companies
in Korea

Performance

Hanmi is a
Pioneer

No path started as a path. Today Hanmi became the protagonist
in the development history of the Korean biopharmaceutical industry.
“First, Most, and Largest” are the indicators that compress the
key performance of Hanmi, overwhelming the industry.

First
Most
Largest

1989
First
USD
6 million

Hanmi Pharmaceutical becomes the first Korean
pharmaceutical company to export a technology
to a global pharmaceutical company
(the largest at the time)
Export of the manufacturing technology for Ceftriaxone to Roche
1997
Largest
USD
74 million

Hanmi Pharmaceutical records the highest technology exports in the pharmaceutical industry at the time
(beating its own record)
Export of micro-emulsion technology to Novartis
2008
Largest
USD
57 billion

Highest ever sales of an incrementally modified drug as of 2008
Hanmi Pharmaceutical releases Amodipin, Korea's first new salt-modified new drug (for high blood pressure)
2009
Largest
USD
78.6 billion

Highest sales ever for a domestically developed, incrementally modified fixed dose combination drug for Amosartan in 2009
Hanmi Pharmaceutical releases
Amosartan, Korea's
first fixed dose
combination new drug
(for high blood pressure)
2013
First
FDA Approval

The FDA approves Esomezol, the world's first incrementally modified new salt version of
Esomeprazole
First case of a new domestic incrementally modified drug
2016
Largest
USD
910 million

Hanmi Pharmaceutical becomes the largest exporter of synthetic new drugs technology in the pharmaceutical industry (surpassing its own record)
Licensing out of Belvarafenib (RAF targeted anti-cancer drug)
2017
First
ISO Certification

Hanmi Pharmaceutical becomes the first pharmaceutical company to obtain the ISO 37001 Certification for Anti-Bribery Management Systems
Esomezole becomes the first drug produced by a Korean pharmaceutical to be listed in the U.S. Pharmacopeia (USP)
2018
Most
122Cases

Hanmi Pharmaceutical registers the most patents in the consolidated approved patent system
The most links between generic licenses and pharmaceutical patents
2019
Most/First

KRW 4.4176 trillion KRW 1.0139 trillion

Records the largest value of prescriptions over the preceding ten years
Hanmi Pharmaceutical becomes the first company to produce KRW 1 trillion worth of products in Korea
Hanmi Pharmaceutical releases new 3-drug fixed dose combination medicines for treating Hypertension (Amosartan Plus, Amosartan Q), which become the first export product to enter the Mexican market.
2020
Most/First
14Cases / AAA

Holds the most blockbuster medicines developed in-house in Korea (UBIST)
Obtains the highest CP grade “AAA” from the Fair Trade Commission for the first time in Korea
Hanmi Pharmaceutical releases Amosartan XQ, the world’s first 4-drug fixed dose combination new medicine
2021
First
4-drug
fixed
dose
combination
Hanmi Pharmaceutical releases
Amosartan XQ, the world's first 4-drug fixed
dose combination new medicine
- Hanmi Pharmaceutical releases the world’s first esomeprazole dual delayed release ‘Esomezole DR’ SR capsule
- Hanmi Pharmaceutical ranks No.1 in outpatient prescriptions for five consecutive years
- Rosuzet records no. 1 sales as a prescription medicine developed by a domestic pharmaceutical company
- New bio drug, Rolontis, receives the world’s first marketing approval in Korea
2022
Most
20Cases

Receives most orphan drug designations among
Korean pharmaceutical companies (US FDA, Europe’s EMA, MFDS)
First novel bioligics to receive FDA approval (Rolvedon), Hanmi Pharmaceutical releases fixed drug combination in China (meiyaping)

We go global through continuous innovation based on
respect, trust, and integrity.

Respect Trust Integrity Innovation Global

Vision & Value

Respect
Hanmi's management philosophy, 'Respect for Humanity', established
by the founder and former chairman Sung-ki Lim, is Hanmi's No. 1
value. Hanmi respects all those who strive for a better life for humankind
and tries to share this value with all stakeholders.
Trust
‘Trust’ is the foundation of Hanmi’s struggle to create better healthcare products and innovative new drugs that don’t yet exist. Hanmi aims to become a role model for Korean biopharmaceutical companies
through trusted and exemplary ethical management.
Integrity
Based on sincerity, Hanmi Pharmaceutical is developing and producing products covering all areas of healthcare and conducting objective and transparent clinical research for new drugs. Integrity is the heart of Hanmi, Which is devoted to a better life for humanity.
Innovation
Creation, Challenge, and ‘Innovation’ are other names for Hanmi Pharmaceutical, which has grown following a path different from others, based on the management philosophy of ‘value creation’. We will keep contributing to a better life for humanity and a happier future through non-stop, daring innovation.
Global
Hanmi, which has led the development of Korea's biopharmaceutical industry through 'Korean R&D' ranging from first generics to
incrementally modified drugs, fixed-dose combinations, and first-in-class drugs, is now starting to take a new leap as Global Hanmi, setting
the standard for the global biopharmaceutical industry.

CEO’s Greeting

<

Thank you for all your trust and love.

Hanmi Pharm, which was established in 1973 has a motto ‘to develop better drugs for precious lives’ and to advance to the global market as a
representative of the Korean Pharmaceutical industry by focusing on R&D.

Hanmi Pharm has achieved the first and greatest new drug licensing deal since 1990’s, and
became a pioneer of developing first-in-class drugs in collaboration with Leading global pharmaceutical companies.

Especially, Hanmi is making strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone’s health and improve their quality of life.

Hanmi has received GMP certifications from food and drugs authorities of developed countries
and alsHanmi Pharm, which was established o strives to promote public health by exporting finished products to global pharmaceutical companies based upon differentiated quality management.

Hanmi has adopted the new slogan “Trust Based Management” to illustrate the company ethos of always being trustworthy and transparent in everything we do. Along with this, Strive to become the world’s most innovative Strive to become the world’s most innovative pharmaceutical company.

Hanmi is pioneering a new way with the spirit of creation and challenge, and will make every effort to strive for continuous improvement in order for our nation to become a leading player in the global pharmaceutical industry.

We believe our responsibility is to devote ourselves to discover global breakthrough drugs Repaying the love and support we receive from you. We look forward to your continued partnership with us.

Thank you.

Chief Executive Officer **Jae-Hyun Park**

Recently, Hanmi has been notified of phishing emails and BEC (Businesss Email Compromise) attacks, pretending to be Hanmi's officer asking for your personal information such as a copy of passport or financial support for new business oppertunities.
Hanmi, or Hanmi's representatives, officers, agents, including but not limited to President, Vice President, CEOs or CFOs, do not send emails asking for your personal information.
Please be aware of these phishing emails and BEC attacks, and do respond to them.

Hanmi Pharmaceutical
is ‘Innovation’.

Overview

Performance

Vision & Core Values

CEO’s Greeting

Hanmi Pharmaceutical is ‘Innovation’.

Overview

Performance

Hanmi Pharmaceutical
is ‘Innovation’.